Market Research Logo

Allergic Rhinitis - Pipeline Review, H2 2016

Allergic Rhinitis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Allergic Rhinitis - Pipeline Review, H2 2016’, provides an overview of the Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis
    • The report reviews pipeline therapeutics for Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Allergic Rhinitis therapeutics and enlists all their major and minor projects
    • The report assesses Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Allergic Rhinitis
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Allergic Rhinitis Overview
    Therapeutics Development
    Pipeline Products for Allergic Rhinitis - Overview
    Pipeline Products for Allergic Rhinitis - Comparative Analysis
    Allergic Rhinitis - Therapeutics under Development by Companies
    Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes
    Allergic Rhinitis - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Allergic Rhinitis - Products under Development by Companies
    Allergic Rhinitis - Products under Investigation by Universities/Institutes
    Allergic Rhinitis - Companies Involved in Therapeutics Development
    3M Drug Delivery Systems
    Accolade Pharmaceuticals, LLC
    AFFiRiS AG
    ALK-Abello A/S
    Allergy Therapeutics Plc
    Ampio Pharmaceuticals, Inc.
    Array BioPharma Inc.
    ASIT biotech s.a.
    Axikin Pharmaceuticals, Inc.
    Chong Kun Dang Pharmaceutical Corp.
    Chrysalis BioTherapeutics, Inc.
    ELORAC, Inc.
    Faes Farma, S.A.
    Fountain Biopharma Inc.
    GlaxoSmithKline Plc
    Glenmark Pharmaceuticals Ltd.
    HAL Allergy BV
    Hisamitsu Pharmaceutical Co., Inc.
    Johnson & Johnson
    Laboratorios LETI S.L.
    Ligand Pharmaceuticals, Inc.
    Marinomed Biotechnologie GmbH
    Merck & Co., Inc.
    Panmira Pharmaceuticals, LLC.
    Paradigm Biopharmaceuticals Limited
    Pfizer Inc.
    Protectimmun GmbH
    Roxall Medizin GmbH
    Sanofi
    Shionogi & Co., Ltd.
    Stallergenes Greer plc
    Sun Pharma Advanced Research Company Ltd.
    Taiho Pharmaceutical Co., Ltd.
    VentiRx Pharmaceuticals, Inc.
    Xencor, Inc.
    Allergic Rhinitis - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (azelastine hydrochloride + budesonide) - Drug Profile
    (fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile
    (levocabastine hydrochloride + mometasone furoate) - Drug Profile
    854-A - Drug Profile
    Allergen for Allergic Asthma and Allergic Rhinitis - Drug Profile
    Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile
    Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile
    Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile
    Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile
    AM-211 - Drug Profile
    AM-461 - Drug Profile
    Ampion - Drug Profile
    AR-460770 - Drug Profile
    Arabinogalactan - Drug Profile
    asapiprant - Drug Profile
    B-244 - Drug Profile
    beta-escin - Drug Profile
    bilastine - Drug Profile
    budesonide - Drug Profile
    CBP-174 - Drug Profile
    cidoxepin hydrochloride - Drug Profile
    clustoid wiesenlieschgras - Drug Profile
    desloratadine - Drug Profile
    emedastine difumarate - Drug Profile
    esketamine hydrochloride - Drug Profile
    FB-825 - Drug Profile
    gp-ASIT - Drug Profile
    GSK-2245035 - Drug Profile
    GSP-301 - Drug Profile
    Lactococcus lactis G121 - Drug Profile
    motolimod - Drug Profile
    nasapaque - Drug Profile
    pentosan polysulfate sodium - Drug Profile
    PF-06444752 - Drug Profile
    PF-06444753 - Drug Profile
    Pollinex Quattro Tree - Drug Profile
    rE58 - Drug Profile
    Small Molecule for Allergic Rhinitis - Drug Profile
    Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile
    Small Molecule to Antagonize G Protein Coupled Receptors for Respiratory Disorders - Drug Profile
    Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis - Drug Profile
    Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile
    STAGR-120 - Drug Profile
    standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
    standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
    SUN-0597 - Drug Profile
    TAS-205 - Drug Profile
    Vaccine to Target IgE for Allergic Rhinitis and Asthma - Drug Profile
    VTX-1463 - Drug Profile
    XmAb-7195 - Drug Profile
    Zafi-3 - Drug Profile
    Allergic Rhinitis - Dormant Projects
    Allergic Rhinitis - Discontinued Products
    Allergic Rhinitis - Product Development Milestones
    Featured News & Press Releases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Allergic Rhinitis, H2 2016
    Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Development by Companies, H2 2016 (Contd..2)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Development by Companies, H2 2016 (Contd..3)
    Products under Development by Companies, H2 2016 (Contd..4)
    Products under Investigation by Universities/Institutes, H2 2016
    Allergic Rhinitis - Pipeline by 3M Drug Delivery Systems, H2 2016
    Allergic Rhinitis - Pipeline by Accolade Pharmaceuticals, LLC, H2 2016
    Allergic Rhinitis - Pipeline by AFFiRiS AG, H2 2016
    Allergic Rhinitis - Pipeline by ALK-Abello A/S, H2 2016
    Allergic Rhinitis - Pipeline by Allergy Therapeutics Plc, H2 2016
    Allergic Rhinitis - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
    Allergic Rhinitis - Pipeline by Array BioPharma Inc., H2 2016
    Allergic Rhinitis - Pipeline by ASIT biotech s.a., H2 2016
    Allergic Rhinitis - Pipeline by Axikin Pharmaceuticals, Inc., H2 2016
    Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
    Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics, Inc., H2 2016
    Allergic Rhinitis - Pipeline by ELORAC, Inc., H2 2016
    Allergic Rhinitis - Pipeline by Faes Farma, S.A., H2 2016
    Allergic Rhinitis - Pipeline by Fountain Biopharma Inc., H2 2016
    Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H2 2016
    Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
    Allergic Rhinitis - Pipeline by HAL Allergy BV, H2 2016
    Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016
    Allergic Rhinitis - Pipeline by Johnson & Johnson, H2 2016
    Allergic Rhinitis - Pipeline by Laboratorios LETI S.L., H2 2016
    Allergic Rhinitis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
    Allergic Rhinitis - Pipeline by Marinomed Biotechnologie GmbH, H2 2016
    Allergic Rhinitis - Pipeline by Merck & Co., Inc., H2 2016
    Allergic Rhinitis - Pipeline by Panmira Pharmaceuticals, LLC., H2 2016
    Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Limited, H2 2016
    Allergic Rhinitis - Pipeline by Pfizer Inc., H2 2016
    Allergic Rhinitis - Pipeline by Protectimmun GmbH, H2 2016
    Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, H2 2016
    Allergic Rhinitis - Pipeline by Sanofi, H2 2016
    Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2016
    Allergic Rhinitis - Pipeline by Stallergenes Greer plc, H2 2016
    Allergic Rhinitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
    Allergic Rhinitis - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
    Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016
    Allergic Rhinitis - Pipeline by Xencor, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Allergic Rhinitis - Dormant Projects, H2 2016
    Allergic Rhinitis - Dormant Projects (Contd..1), H2 2016
    Allergic Rhinitis - Dormant Projects (Contd..2), H2 2016
    Allergic Rhinitis - Dormant Projects (Contd..3), H2 2016
    Allergic Rhinitis - Dormant Projects (Contd..4), H2 2016
    Allergic Rhinitis - Dormant Projects (Contd..5), H2 2016
    Allergic Rhinitis - Dormant Projects (Contd..6), H2 2016
    Allergic Rhinitis - Dormant Projects (Contd..7), H2 2016
    Allergic Rhinitis - Dormant Projects (Contd..8), H2 2016
    Allergic Rhinitis - Dormant Projects (Contd..9), H2 2016
    Allergic Rhinitis - Discontinued Products, H2 2016
    Allergic Rhinitis - Discontinued Products (Contd..1), H2 2016
    Allergic Rhinitis - Discontinued Products (Contd..2), H2 2016
    List of Figures
    Number of Products under Development for Allergic Rhinitis, H2 2016
    Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Top 10 Routes of Administration, H2 2016
    Number of Products by Stage and Top 10 Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report